Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 74 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
patients diagnosed as malignant lymphoma
patients who were refractory to anthracycline or anthraquinone containing chemotherapy
patients who are going to receive ESHAP or CHASE treatment regimen
ECOG performance status =< 2
patients who have appropriate bone marrow, hepatic and renal functions
written informed consent
history of bone marrow transplantation or PBSCT
more than 2 prior chemotherapy regimens
primary hematologic disease such as myelodysplastic syndrome
previous radiotherapy within 4 weeks of enrollment
woman of childbearing potential who were either pregnant, breast feeding
patients who participated in other clinical trials within the last 4 weeks of enrollment